Skip to content

Haemonetics HAE Contract with Customer, Liability

Contract with Customer, Liability at other companies

Abbott logo
AbbottABT
Boston Scientific logo
Boston ScientificBSX
Medtronic logo
MedtronicMDT
LivaNova logo
LivaNovaLIVN
ICU Medical logo
ICU MedicalICUI
Danaher logo
DanaherDHR

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's contract with customer, liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's contract with customer, liability?
Haemonetics (HAE) reported contract with customer, liability of $44.6M in Q4 2025.
How has Haemonetics's contract with customer, liability changed year-over-year?
Haemonetics's contract with customer, liability increased by 25.3% year-over-year, from $35.6M to $44.6M.
What is the long-term trend for Haemonetics's contract with customer, liability?
Over 4 years (2021 to 2025), Haemonetics's contract with customer, liability has grown at a 20.0% compound annual growth rate (CAGR), from $20.9M to $43.3M.